Literature DB >> 19122111

Alzheimer disease: time to improve its diagnosis and treatment.

Stephen Salloway1, Stephen Correia.   

Abstract

Basic research is bringing a much-needed infusion of optimism and urgency to the clinical diagnosis and treatment of Alzheimer disease. Some of its risk factors may be modifiable, and although current drugs offer only modest benefit, true disease-modifying drugs are on the horizon. This review is aimed at primary care physicians, who are the first clinicians to see patients with Alzheimer disease and are responsible for their ongoing care throughout the course of their dementia.

Entities:  

Mesh:

Year:  2009        PMID: 19122111     DOI: 10.3949/ccjm.76a.072178

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  11 in total

1.  Current guidelines for dementia screening: shortcomings and recommended changes.

Authors:  Magdalena I Tolea; James E Galvin
Journal:  Neurodegener Dis Manag       Date:  2013-12

2.  Circulating Antibodies to IDO/THO Pathway Metabolites in Alzheimer's Disease.

Authors:  S Duleu; A Mangas; F Sevin; B Veyret; A Bessede; M Geffard
Journal:  Int J Alzheimers Dis       Date:  2010-03-15

Review 3.  Changing perspectives regarding late-life dementia.

Authors:  Majid Fotuhi; Vladimir Hachinski; Peter J Whitehouse
Journal:  Nat Rev Neurol       Date:  2009-11-17       Impact factor: 42.937

4.  Central angiotensin II stimulation promotes β amyloid production in Sprague Dawley rats.

Authors:  Donglin Zhu; Jingping Shi; Yingdong Zhang; Bianrong Wang; Wei Liu; Zhicong Chen; Qiang Tong
Journal:  PLoS One       Date:  2011-01-28       Impact factor: 3.240

5.  Understanding the Pathophysiology of Alzheimer's Disease and Mild Cognitive Impairment: A Mini Review on fMRI and ERP Studies.

Authors:  Takao Yamasaki; Hiroyuki Muranaka; Yumiko Kaseda; Yasuyo Mimori; Shozo Tobimatsu
Journal:  Neurol Res Int       Date:  2011-07-07

6.  Impact of early intervention and disease modification in patients with predementia Alzheimer's disease: a Markov model simulation.

Authors:  David Budd; Leah C Burns; Zhenchao Guo; Gilbert L'italien; Pablo Lapuerta
Journal:  Clinicoecon Outcomes Res       Date:  2011-10-07

7.  Beneficial effect of diosgenin as a stimulator of NGF on the brain with neuronal damage induced by Aβ-42 accumulation and neurotoxicant injection.

Authors:  Eun-Kyoung Koh; Woo-Bin Yun; Ji-Eun Kim; Sung-Hwa Song; Ji-Eun Sung; Hyun-Ah Lee; Eun-Ji Seo; Seung-Wan Jee; Chang-Joon Bae; Dae-Youn Hwang
Journal:  Lab Anim Res       Date:  2016-06-24

Review 8.  Early Stage Glycosylation Biomarkers in Alzheimer's Disease.

Authors:  Patricia Regan; Paula L McClean; Thomas Smyth; Margaret Doherty
Journal:  Medicines (Basel)       Date:  2019-09-03

9.  Effect of Resveratrol on Reactive Oxygen Species-Induced Cognitive Impairment in Rats with Angiotensin II-Induced Early Alzheimer's Disease .

Authors:  Yu-Te Lin; Yi-Chung Wu; Gwo-Ching Sun; Chiu-Yi Ho; Tzyy-Yue Wong; Ching-Huang Lin; Hsin-Hung Chen; Tung-Chen Yeh; Chia-Jung Li; Ching-Jiunn Tseng; Pei-Wen Cheng
Journal:  J Clin Med       Date:  2018-10-05       Impact factor: 4.241

Review 10.  An Overview of the Intrinsic Role of Citrullination in Autoimmune Disorders.

Authors:  Mohammed Alghamdi; Doaa Alasmari; Amjad Assiri; Ehab Mattar; Abdullah A Aljaddawi; Sana G Alattas; Elrashdy M Redwan
Journal:  J Immunol Res       Date:  2019-11-25       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.